Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#41 / 200 Total
AWIN - AERWINS Technologies Inc - Stock Price Chart
TickerAWIN [NASD]
CompanyAERWINS Technologies Inc
CountryUSA
IndustryScientific & Technical Instruments
Market Cap1.54MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-99.99%
Dividend-Sales Q/Q-
Insider Own32.61%Inst Own2.69%
Insider Trans0.00%Inst Trans-
Short Float2.40%Earnings-
Analyst Recom1.00Target Price100.00
Avg Volume81.71K52W Range2.70 - 91.00
AERWINS Technologies, Inc. engages in the development of technologies to enable air mobility. It has developed XTURISMO, a hoverbike, and the C.O.S.M.O.S. flight operation management system. It also offers drone-based solution services. The company was founded in 2017 and is headquartered in Middletown, DE.
CMAX - CareMax Inc - Stock Price Chart
TickerCMAX [NASD, RUT]
CompanyCareMax Inc
CountryUSA
IndustryHealth Information Services
Market Cap10.89MEPS (ttm)-161.56
P/E-EPS this Y86.71%
Forward P/E-EPS next Y38.21%
PEG-EPS past 5Y-
P/S0.01EPS next 5Y-
P/B0.17EPS Q/Q-4113.58%
Dividend-Sales Q/Q-7.57%
Insider Own38.16%Inst Own45.44%
Insider Trans0.00%Inst Trans-13.09%
Short Float9.64%EarningsMar 18/b
Analyst Recom3.00Target Price4.80
Avg Volume96.21K52W Range2.23 - 126.00
CareMax, Inc. provides medical services through physicians and health care professionals. It offers a suite of health care and social services to its patients, including primary care, specialty care, telemedicine, health and wellness, optometry, dental, pharmacy, and transportation. The company was founded by Carlos de Solo and Alberto de Solo in 2011, and is headquartered in Miami, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Omachonu VincentDirectorMay 12 '23Option Exercise0.0016,187029,687May 16 08:48 PM
BRKL - Brookline Bancorp, Inc. - Stock Price Chart
TickerBRKL [NASD, RUT]
CompanyBrookline Bancorp, Inc.
CountryUSA
IndustryBanks - Regional
Market Cap748.45MEPS (ttm)0.92
P/E9.17EPS this Y5.69%
Forward P/E7.63EPS next Y22.82%
PEG1.53EPS past 5Y-3.99%
P/S1.20EPS next 5Y6.00%
P/B0.63EPS Q/Q83.70%
Dividend6.56%Sales Q/Q13.02%
Insider Own2.97%Inst Own79.17%
Insider Trans-1.25%Inst Trans1.00%
Short Float1.63%EarningsApr 24/a
Analyst Recom1.80Target Price12.80
Avg Volume455.19K52W Range7.00 - 11.52
Brookline Bancorp, Inc. is a multi-bank holding company that engages in the provision of financial solutions through its subsidiaries. The firm offers a range of commercial, business, and retail banking services, including cash management products, on-line banking services, consumer and residential loans, and investment services for small to mid-sized businesses and retail customers. It also provides equipment financing services. The company was founded on November 1, 1997 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cosman James MChief Operations OfficerMar 12 '24Sale9.6616,000154,56069,873Mar 13 04:11 PM
Cosman James MChief Operations OfficerMar 08 '24Sale10.0016,000160,00069,873Mar 08 04:32 PM
HACKETT JOHN ADirectorNov 07 '23Sale9.133,50031,95537,998Nov 07 03:01 PM
Hill Willard I JRDirectorNov 02 '23Buy8.552,00017,10023,631Nov 03 10:00 AM
Goldrick Michael PCEO PCSB BankJun 06 '23Buy8.715,00043,55014,152Jun 06 12:58 PM
GSHD - Goosehead Insurance Inc - Stock Price Chart
TickerGSHD [NASD, RUT]
CompanyGoosehead Insurance Inc
CountryUSA
IndustryInsurance - Diversified
Market Cap1.33BEPS (ttm)0.62
P/E85.59EPS this Y16.06%
Forward P/E25.04EPS next Y37.56%
PEG4.95EPS past 5Y-
P/S4.98EPS next 5Y17.30%
P/B20.10EPS Q/Q1528.57%
Dividend-Sales Q/Q11.22%
Insider Own3.52%Inst Own102.57%
Insider Trans-40.41%Inst Trans0.89%
Short Float10.79%EarningsApr 24/a
Analyst Recom1.75Target Price84.09
Avg Volume324.35K52W Range53.57 - 92.76
Goosehead Insurance, Inc. is a holding company, which engages in the provision of independent personal lines of insurance. The company was founded by Robyn Jones and Mark E. Jones in 2003 and is headquartered in Westlake, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mark & Robyn Jones DescendantsMember of 10% owner groupFeb 29 '24Sale75.8750,0003,793,3430Mar 04 09:53 PM
Cruzado WadedDirectorFeb 28 '24Buy75.1025018,775343Mar 04 09:49 PM
Mark & Robyn Jones DescendantsMember of 10% owner groupFeb 28 '24Sale74.9236,3372,722,5010Feb 28 07:40 PM
Mark & Robyn Jones DescendantsMember of 10% owner groupFeb 27 '24Sale74.199,729721,7950Feb 28 07:40 PM
Miller MarkPresident and COOFeb 26 '24Buy73.865,000369,27520,000Feb 27 06:16 PM
CNMD - Conmed Corp. - Stock Price Chart
TickerCNMD [NYSE, RUT]
CompanyConmed Corp.
CountryUSA
IndustryMedical Devices
Market Cap1.91BEPS (ttm)2.61
P/E23.70EPS this Y24.46%
Forward P/E11.26EPS next Y28.01%
PEG0.93EPS past 5Y7.64%
P/S1.52EPS next 5Y25.40%
P/B2.23EPS Q/Q980.96%
Dividend1.29%Sales Q/Q5.68%
Insider Own0.79%Inst Own116.75%
Insider Trans-1.42%Inst Trans2.18%
Short Float12.75%EarningsApr 24/a
Analyst Recom1.88Target Price111.12
Avg Volume596.83K52W Range69.78 - 138.47
CONMED Corp. is a medical technology company, which engages in providing devices and equipment for surgical procedures. Its products include AirSeal and insufflation, allograft cartilage and tissue, arthroplasty, biliary and endoscopic ultrasound, biomedical sensors and electrodes, biopsy and polypectomy, dilators and accessories, electrosurgical units, fixation devices, hemostasis, implants and suture anchors, infection prevention, patient positioning, and related products. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cohen Heather LEVP & Chief HR & Legal OfficerMar 08 '24Option Exercise68.9152,5003,617,90059,612Mar 11 04:42 PM
Lalomia BrentVice President QA and RAMar 07 '24Option Exercise0.00750983Mar 11 11:44 AM
Peters Stanley W IIIPresident AS and AETDec 04 '23Option Exercise41.932,30096,4392,363Dec 06 12:12 PM
Peters Stanley W IIIPresident AS and AETDec 04 '23Sale109.932,300252,83363Dec 06 12:12 PM
Peters Stanley W IIIPresident AS and AETNov 07 '23Option Exercise41.931,20050,3161,263Nov 09 01:42 PM
OCEA - Ocean Biomedical Inc. - Stock Price Chart
TickerOCEA [NASD, RUT]
CompanyOcean Biomedical Inc.
CountryUSA
IndustryBiotechnology
Market Cap43.49MEPS (ttm)-3.83
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-587.66%
Dividend-Sales Q/Q-
Insider Own74.86%Inst Own13.50%
Insider Trans0.00%Inst Trans2.64%
Short Float7.39%Earnings-
Analyst Recom1.00Target Price18.50
Avg Volume6.80M52W Range0.52 - 12.08
Apr-24-24 04:51PM Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K (GlobeNewswire)
Mar-28-24 01:15PM 13 Hot Stocks to Invest in According to Wall Street Analysts (Insider Monkey) -6.77%
08:01AM Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL (GlobeNewswire)
Mar-24-24 03:52PM 5 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Mar-05-24 08:30AM Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments (GlobeNewswire) +28.92%
Feb-29-24 08:01AM Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting (GlobeNewswire) +14.29%
Dec-05-23 09:45AM EXCLUSIVE: Ocean Biomedical Announces Publication of Breast Cancer Research On New Tumor Suppression Pathway for Proprietary Antibody (Benzinga)
08:15AM Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody (GlobeNewswire)
Nov-29-23 05:41PM Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire) -8.95%
Nov-14-23 08:01AM Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics (GlobeNewswire) -15.36%
Ocean Biomedical, Inc. is a biopharmaceutical company. It engages in the business of discovering and developing therapeutic products in oncology, fibrosis, infectious diseases and inflammation. The company was founded by Chirinjeev Kathuria in June 2021 and is headquartered in Providence, RI.
AZZ - AZZ Inc - Stock Price Chart
TickerAZZ [NYSE, RUT]
CompanyAZZ Inc
CountryUSA
IndustrySpecialty Business Services
Market Cap1.84BEPS (ttm)3.00
P/E24.40EPS this Y9.09%
Forward P/E12.94EPS next Y14.53%
PEG2.44EPS past 5Y12.02%
P/S1.20EPS next 5Y10.00%
P/B2.62EPS Q/Q744.34%
Dividend0.93%Sales Q/Q8.93%
Insider Own2.43%Inst Own90.93%
Insider Trans0.00%Inst Trans-7.32%
Short Float1.36%EarningsApr 22/b
Analyst Recom2.00Target Price83.50
Avg Volume167.06K52W Range34.59 - 84.52
AZZ, Inc. engages in the provision of hot-dip galvanizing and coil coating solutions. It operates through the following segments: AZZ Metal Coatings, AZZ Precoat Metals, and AZZ Infrastructure Solutions. The AZZ Metal Coatings segment provides metal finishing solutions for corrosion protection including hot-dip galvanizing, spin galvanizing, powder coating, anodizing, and plating. The AZZ Precoat Metals segment includes aesthetic and corrosion protective coatings and related value-added services for steel and aluminum coil. The AZZ Infrastructure Solutions delivers transmission of power from generation sources. The company was founded in 1956 and is headquartered in Fort Worth, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Russell Kurt L.COO - Precoat MetalsMay 12 '23Option Exercise0.0015,122018,122May 16 05:01 PM
FERGUSON THOMAS EPresident and CEOMay 09 '23Option Exercise0.008,0620201,385May 11 04:41 PM
Mackey Tara DChief Legal OfficerMay 09 '23Option Exercise0.001,745028,116May 11 04:42 PM
Schlom Philip ASVP, Chief Financial OfficerMay 09 '23Option Exercise0.002,103015,966May 11 04:42 PM
Stovall Bryan LeeCOO - Metal CoatingsMay 09 '23Option Exercise0.002,122034,420May 11 04:43 PM
ACRV - Acrivon Therapeutics Inc - Stock Price Chart
TickerACRV [NASD, RUT]
CompanyAcrivon Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap261.47MEPS (ttm)-2.73
P/E-EPS this Y-8.00%
Forward P/E-EPS next Y0.98%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.57EPS Q/Q-101.64%
Dividend-Sales Q/Q-
Insider Own32.95%Inst Own62.09%
Insider Trans30.09%Inst Trans-
Short Float4.95%EarningsMar 28/b
Analyst Recom1.00Target Price21.22
Avg Volume757.92K52W Range3.19 - 14.30
Apr-24-24 04:01PM Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event (GlobeNewswire)
Apr-16-24 08:01PM Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 (GlobeNewswire)
Apr-10-24 08:00AM Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368 (GlobeNewswire) +8.00%
Apr-09-24 10:32AM ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost (InvestorPlace) +62.77%
07:00AM Acrivon Therapeutics Announces $130 Million Private Placement Financing (GlobeNewswire)
Mar-30-24 05:31AM Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ... (GuruFocus.com)
Mar-28-24 12:52PM ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +10.60%
08:00AM Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 (GlobeNewswire)
Mar-04-24 08:00AM Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors (GlobeNewswire) -11.40%
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerApr 11 '24Buy8.502,353,00020,000,5005,360,858Apr 15 08:53 AM
Chione Ltd10% OwnerJun 26 '23Sale12.93162073,848,632Jun 28 03:47 PM
Holm-Jorgensen RasmusChief Financial OfficerJun 16 '23Option Exercise3.639,50034,48529,530Jun 20 05:21 PM
Chione Ltd10% OwnerJun 15 '23Sale12.142,05624,9603,848,648Jun 20 05:15 PM
Chione Ltd10% OwnerJun 14 '23Sale12.1389310,8323,850,704Jun 14 06:33 PM
XRTX - XORTX Therapeutics Inc - Stock Price Chart
TickerXRTX [NASD]
CompanyXORTX Therapeutics Inc
CountryCanada
IndustryBiotechnology
Market Cap5.18MEPS (ttm)-1.11
P/E-EPS this Y-63.97%
Forward P/E-EPS next Y46.29%
PEG-EPS past 5Y26.21%
P/S-EPS next 5Y-
P/B1.12EPS Q/Q201.85%
Dividend-Sales Q/Q-
Insider Own10.30%Inst Own8.59%
Insider Trans0.00%Inst Trans-
Short Float1.18%EarningsApr 02/b
Analyst Recom1.00Target Price12.15
Avg Volume50.18K52W Range1.98 - 7.52
XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.
META - Meta Platforms Inc - Stock Price Chart
TickerMETA [NASD, NDX, S&P 500]
CompanyMeta Platforms Inc
CountryUSA
IndustryInternet Content & Information
Market Cap1121.33BEPS (ttm)17.41
P/E25.35EPS this Y35.28%
Forward P/E19.02EPS next Y15.33%
PEG0.98EPS past 5Y14.46%
P/S7.86EPS next 5Y26.00%
P/B7.49EPS Q/Q114.26%
Dividend0.41%Sales Q/Q27.26%
Insider Own14.03%Inst Own67.62%
Insider Trans-1.44%Inst Trans-1.62%
Short Float1.24%EarningsApr 24/a
Analyst Recom1.44Target Price525.65
Avg Volume18.74M52W Range207.13 - 531.49
Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Newstead JenniferChief Legal OfficerApr 23 '24Sale491.25585287,38137,228Apr 25 06:24 PM
Olivan JavierChief Operating OfficerApr 19 '24Sale501.18490245,5787,089Apr 23 06:14 PM
Newstead JenniferChief Legal OfficerApr 16 '24Sale498.59585291,67537,813Apr 18 06:05 PM
Olivan JavierChief Operating OfficerApr 12 '24Sale517.75490253,6987,579Apr 16 06:10 PM
Newstead JenniferChief Legal OfficerApr 09 '24Sale522.00585305,37038,398Apr 11 06:06 PM
1234567891020